Theriva Biologics
TOVX
18 hedge funds and large institutions have $443K invested in Theriva Biologics in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
6% more funds holding
Funds holding: 17 → 18 (+1)
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
47% less capital invested
Capital invested by funds: $830K → $443K (-$388K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$112K |
| 2 |
Renaissance Technologies
New York
|
+$48.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$48.7K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$9.34K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$2.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$278K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$67K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$1.71K |
| 5 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$342 |
TOVX Hedge Fund Activity: Q1 2020 in Review
18 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2020, worth a combined $443K — down 47% from $830K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TOVX positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $112K. The largest seller was Sabby Management, cutting an estimated $278K.
- 18 institutional investors held Theriva Biologics (TOVX) as of Q1 2020, up from 17 in Q4 2019.
- Funds reported $443K of Theriva Biologics stock for Q1 2020, down 47% quarter-over-quarter.
- 6 funds opened new Theriva Biologics positions in Q1 2020 and 3 closed out, a net change of +3 holders.
- The largest Theriva Biologics buyer in Q1 2020 was Susquehanna International Group, an estimated $112K added.
- The largest Theriva Biologics seller in Q1 2020 was Sabby Management, an estimated $278K sold.
Based on aggregated 13F filings for Q1 2020.